DAIICHI SANKYO, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2

Recruiting

Conditions: Advanced Solid Tumor
Melanoma
Bladder Cancer
Cervical Cancer
Esophageal Cancer
Gastric Cancer
Ovarian Carcinoma
Pancreatic Carcinoma
Head and Neck Cancer
Endometrial Cancer

Interventions: Drug: HER3-DXd

First Posted Date: 2023-12-15

Last Posted Date: 2024-05-31

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 400

Registration Number: NCT06172478

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Japan
🇺🇸
Washington University, School of Medicine, Saint Louis, Missouri, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 7 locations

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Solid Cancer

Interventions: Drug: R-DXd
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Topotecan
Drug: PLD

First Posted Date: 2023-12-07

Last Posted Date: 2024-11-19

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 650

Registration Number: NCT06161025

Locations: 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳
Hubei Cancer Hospital, Wuhan, China
🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of

and more 78 locations

Medical Access Program for Patritumab Deruxtecan

Conditions: Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

First Posted Date: 2023-10-25

Last Posted Date: 2024-12-06

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT06099639

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States

and more 14 locations

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

Completed

Conditions: Hormone-receptor-positive Breast Cancer
HER2-low Breast Cancer
HER2-negative Breast Cancer

Interventions: Other: No drug

First Posted Date: 2023-09-15

Last Posted Date: 2024-02-26

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 927

Registration Number: NCT06040593

Locations: 🇺🇸
ConcertAI database, Cambridge, Massachusetts, United States

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

Phase 1

Recruiting

Conditions: Netherton Syndrome

Interventions: Other: Placebo
Drug: DS-2325a

First Posted Date: 2023-08-07

Last Posted Date: 2024-06-21

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 12

Registration Number: NCT05979831

Locations: 🇫🇷
Saint Louis Hospital, Paris, France

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab Deruxtecan

First Posted Date: 2023-07-18

Last Posted Date: 2024-12-04

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 250

Registration Number: NCT05950945

Locations: 🇧🇷
Catarina Pesquisa Clinica, Santa Catarina, Brazil
🇧🇷
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo André, Brazil
🇧🇪
Universitair Ziekenhuis Brussel, Bruxelles, Belgium

and more 42 locations

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Metastatic Solid Tumor
Advanced Solid Tumor

Interventions: Drug: DS-3939a

First Posted Date: 2023-05-25

Last Posted Date: 2024-10-23

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 430

Registration Number: NCT05875168

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
The Medical College of Wisconsin, INC, Milwaukee, Wisconsin, United States

and more 11 locations

A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation

Recruiting

Conditions: Atrial Fibrillation

Interventions: Drug: Edoxaban

First Posted Date: 2023-04-07

Last Posted Date: 2024-07-29

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 1100

Registration Number: NCT05804747

Locations: 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of

and more 30 locations

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

Completed

Conditions: HER2-positive Breast Cancer

First Posted Date: 2023-03-15

Last Posted Date: 2023-08-16

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 865

Registration Number: NCT05769751

Locations: 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China

and more 2 locations

A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Other: Archival tissue specimen and immunohistochemistry staining

First Posted Date: 2023-03-15

Last Posted Date: 2023-04-10

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 225

Registration Number: NCT05769764

Locations: 🇺🇸
Baptist Health South Florida - Miami Cancer Institute, Miami, Florida, United States
🇺🇸
McLeod Health, Florence, South Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy